search icon

    Market Snapshot

    • S&P Futures

      4,205.75

    • Dow Futures

      33,281

    • Nasdaq Futures

      13,304

    blog search icon

    Synthetic Biologics, Inc.

    (AMEX:SYN)

    $1.41

    -$0.01

    -0.70%

    Synthetic Biologics, Inc. Chart

    SYN Stock Price Today

    Synthetic Biologics, Inc. (SYN) stock declined over -0.70% intraday to trade at $1.41 a share on AMEX. The stock opened with a gain of 0.71% at $1.46 and touched an intraday high of $1.49, rising 1.44% against the last close of $1.39. The stock went to a low of $1.36 during the session.

    Stock Snapshot

    $1.39

    Prev. Close

    187.5 Million

    Market Cap

    $1.36

    Day Low

    $1.46

    Open

    132.04 Million

    Number of Shares

    $1.49

    Day High

    -

    P/E ratio

    -1.20

    EPS (TTM)

    3.58

    Cash Flow per Share

    1.44

    Free Float in %

    0.56

    Book Value

    161,869

    Volume

    Synthetic Biologics, Inc. Historical Data

    DateOpenHighLowCloseVolume
    2022-08-10$1.46$1.49$1.36$1.42334,987
    2022-08-09$1.4$1.43$1.39$1.39170,000
    2022-08-08$1.45$1.47$1.4$1.43205,600
    2022-08-05$1.48$1.5$1.38$1.45508,300
    2022-08-04$1.75$1.9$1.54$1.572,955,400
    2022-08-03$1.41$1.59$1.4$1.48982,800
    2022-08-02$1.37$1.44$1.37$1.41135,800
    2022-08-01$1.43$1.46$1.35$1.37162,200
    2022-07-29$1.5$1.5$1.42$1.44119,800
    2022-07-28$1.45$1.49$1.4$1.4281,400

    Contact Details

    9605 Medical Center Drive
    Suite 270
    Rockville, MD 20850
    United States

    Webiste:SYN

    301 417 4364

    Company Information

    Employees-

    Beta1.36

    Sales or Revenue0

    5Y Sales Change-

    Fiscal Year Ends2021-12-30

    SectorHealth Care

    IndustryBiotechnology

    About Company

    Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland.

    Frequently Asked Questions

    icon

    What is the current Synthetic Biologics, Inc. (SYN) stock price?

    Synthetic Biologics, Inc. (AMEX: SYN) stock price is $1.41 as of the last check on Wednesday, August 10. During the trading session, SYN stock reached the peak price of $1.49 while $1.36 was the lowest point it dropped to.

    icon

    SYN's industry and sector of operation?

    The AMEX listed SYN is part of Biotechnology industry that operates in the broader Health Care sector. Synthetic Biologics, Inc. , a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need.

    icon

    Who are the executives of SYN?

    Mr. Steven A. Shallcross CPA
    CEO, CFO, Treasurer, Corp. Sec. & Director
    Dr. Frank Tufaro Ph.D.
    Chief Operating Officer
    Vincent I. Perrone
    Director of Corp. Communication
    Dr. Vince Wacher
    Head of Product and Corp. Devel.

    icon

    What is the SYN stock price today?

    SYN stock traded closed the last session at $1.42, which is -$0.010000000000000009 or -0.7042253521126767% lower than its previous close of $1.39. SYN's current trading price is 5.19% lower than its 52-week high of $5.57 where as its distance from 52-week low of 1.35% is -74.53%.

    icon

    How many employees does SYN have?

    Number of SYN employees currently stands at -. SYN operates from 9605 Medical Center Drive, Suite 270, Rockville, MD 20850, United States.

    icon

    Link for SYN official website?

    Official Webiste of $SYN is: https://www.syntheticbiologics.com

    icon

    How do I contact SYN?

    SYN could be contacted at SYN operates from 9605 Medical Center Drive, Suite 270, Rockville, MD 20850, United States, or at phone #301 417 4364 and can also be accessed through its website.

    icon

    How many shares of SYN are traded daily?

    SYN stock volume for the day was 161,869 shares while in the previous session number of SYN shares traded was 334,987 . The average number of SYN shares traded daily for last 3 months was 187.76 Thousands.

    icon

    How much did SYN change today?

    The percentage change in SYN stock occurred in the recent session was -0.7042253521126767% while the dollar amount for the price change in SYN stock was -$0.010000000000000009.

    icon

    What price range SYN stock been trading in?

    In the recent session, the day high for SYN stock was $1.49 while the low for SYN stock touched on the day was $1.36.

    icon

    What is the market cap of SYN currently?

    The market value of SYN currently stands at 187.5 Million with its latest stock price at $1.41 and 132.04 Million of its shares outstanding.